

## **Slowness as a predictor of functional decline in older adults: Comparison of Moberg picking-up test and walking speed**

Nazanin Abolhassani PhD<sup>1,2</sup>, Sarah Fustinoni BSc<sup>1</sup>, Yves Henchoz PhD<sup>1</sup>

<sup>1</sup>Department of Epidemiology and Health Systems, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland

<sup>2</sup>Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

Corresponding author:

Nazanin Abolhassani

Department of Epidemiology and Health Systems, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland

Addressee: Route de la Corniche 10, 1010 Lausanne, Switzerland.

Email: nazanin.abolhassani@unisante.ch

**Funding:** This work was supported by the operating budget of the Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland. Since its start in 2004, the data collection of the Lc65+ study has been funded by the following Swiss public and nonprofit institutions: Canton de Vaud Department of Public Health; Lausanne University Hospital; Center for Primary Care and Public Health (Unisanté), University of Lausanne; Faculty of Biology and Medicine, University of Lausanne; City of Lausanne; Loterie Romande (a nonprofit organization supporting research and social projects); Fondation Médecine Sociale et Préventive, Lausanne; and Fondation Esther Locher-Gurtner, Lausanne.

**Sponsor's Role:** Sponsors had no role in the design, methods, data collections, analysis and preparation of the study.

**Main text word count:** 3246

**Conflict of interests:** The authors declare no conflicts of interest.

**Author Contributions:** All authors designed the study, YH conducted the Lc65+ data collection, NA performed and SF supervised statistical analyses, NA wrote the manuscript; all authors interpreted the data, critically reviewed and approved the final version of the manuscript.

**Brief summary:** This article compares the capacity of slowness measurements (Moberg picking up test (MPUT) and walking speed) in older adults to predict non-fatal adverse consequences of frailty. MPUT may be an alternative measurement of slowness.

**Acknowledgments:** We would like to thank all Lc65+ participants and the whole team of collaborators involved in the data collection and management. We are also deeply grateful to Prof. Brigitte Santos-Eggimann for her advice.

1 **Title: Slowness as a predictor of functional decline in older adults: Comparison of Moberg picking-**  
2 **up test and walking speed**

3 **ABSTRACT**

4 **Objectives:** Slowness, generally assessed by walking speed (WS), is an estimator of frailty and its  
5 outcomes. Because of potential difficulties in assessing WS, the Moberg picking-up test (MPUT) might  
6 be an alternative. This study investigated the capacity of slowness measurements (WS and MPU) to  
7 predict non-fatal adverse consequences of frailty, primarily: decline in basic activities of daily living  
8 (BADLs); and secondarily: decline in instrumental activities of daily living (IADLs), fall, hospitalization  
9 and incident disease.

10 **Design:** Observational (prospective longitudinal study)

11 **Setting and participants:** This study used data from the population-based Lausanne cohort 65+. At  
12 baseline, 1887 individuals (aged 72-77 years) completed both WS (time to walk 20-meters at usual  
13 pace) and MPU (time to pick up 12 objects) assessments.

14 **Methods:** All outcomes, assessed at 1-year and 4-year follow-ups, were entered in separate logistic  
15 regression models with adjustment for age, sex and respective values at baseline. The prediction of all  
16 outcomes by either WS or MPU was assessed using area under the ROC curve (AUC) and compared  
17 by chi-squared tests.

18 **Results:** There were positive associations between slowness either assessed by WS (RR=2.48; P-  
19 value<0.001) or MPU (RR=1.91; P-value<0.001) and decline in BADLs at 1-year follow-up. These  
20 associations remained significant at 4-year follow-up for both WS (RR=2.28; P-value<0.001) and MPU  
21 (RR=1.95; P-value<0.001). There was no significant difference between predictive values of slow WS  
22 and MPU for decline in BADLs at 1-year (P-value: 0.328) and 4-year follow-ups (P-value: 0.413). The  
23 prediction was not significantly different for secondary outcomes, except for decline in IADLs for which  
24 the prediction was slightly better for WS.

25 **Conclusions and Implications:** MPU may be an alternative measurement of slowness with predictive  
26 value of functional decline. No significant difference in predictive capabilities of MPU and WS for  
27 specific adverse consequences of frailty is promising in favor of using MPU for measuring slowness.

28 **KEYWORDS:** Walking speed; Moberg picking-up test; slowness; frailty.

29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 *This is a post-peer-review, pre-copyedit version of an article published in J Am Med Dir Assoc. The final*  
41 *authenticated version is available online at: <https://doi.org/10.1016/j.jamda.2022.07.016>*

## 42 INTRODUCTION

43 With the increase in life expectancy, older adults make up a large population portion. Population aging  
44 is accelerating rapidly worldwide, from 461 million people older than 65 years in 2004 to an estimated  
45 2 billion people by 2050<sup>1</sup>. In 2015, 17.4 percent of Europeans were aged 65 or older. Europe is further  
46 along in the demographic transition and will remain the oldest region in the world through 2050; and  
47 this trend is expected to accelerate between 2030 and 2050<sup>2,3</sup>. The rapid expansion of the aging  
48 population has brought a concomitant rise in the number of older adults with frailty and related risk  
49 of adverse outcomes such as disability, fall, hospitalisation and premature death<sup>4-7</sup>. While frailty is  
50 widely used, research is still ongoing on the definition and assessment of this concept<sup>8</sup>. Although there  
51 is no consensus on a frailty definition, Fried's phenotype model with five dimensions (shrinking,  
52 weakness, exhaustion, slowness, and low physical activity) is one of the most evaluated and commonly  
53 used<sup>8-10</sup>.

54 Among the five criteria of the frailty phenotype, slowness is considered as the main warning sign of  
55 functional decline in older adults<sup>11</sup>. Generally assessed by walking speed (WS)<sup>9</sup>, slowness is in itself a  
56 widely used criterion in geriatric assessment, and has become a good single estimator of frailty and its  
57 outcomes<sup>12,13</sup>. As a reliable and sensitive measure of functional ability closely associated with frailty  
58 and survival in older adult populations, WS has been referred to as the "6th vital sign"<sup>14-17</sup>. However,  
59 there are potential difficulties in assessing WS in terms of the space needed and its feasibility for  
60 people with certain conditions such as mobility problem. While most studies about reliability of WS as  
61 the predictor of adverse health outcomes among community-dwelling adults were based on  
62 measurements in clinical settings, there is evidence that WS assessed in laboratory setting may not  
63 fully reflect the WS of individuals in their everyday life context<sup>18-20</sup>. Therefore, due to difficulties and  
64 limitations of assessing WS, whether in ecological or clinical settings, alternative measurement  
65 methods may be useful.

66 The Moberg picking-up test (MPUT) is a timed test first developed in neurorehabilitation to evaluate  
67 hand motor activity. It consists in picking up several small objects to put them in a box, as fast as  
68 possible <sup>21</sup>. As the time to complete the task is measured, MPUT might be an option for measuring  
69 slowness in older populations; in addition, it is simple, quick to administer, easy to replicate, and  
70 inexpensive to acquire <sup>22</sup>; furthermore MPUT can improve the issue of biased estimates due to non-  
71 random exclusion of individuals unable to complete WS <sup>23</sup>. A previous study on slowness measurement  
72 in old age showed a positive association between WS and MPUT <sup>24</sup>. Also, another study comparing WS  
73 and MPUT in predicting mortality as an adverse outcome of age-related frailty showed an association  
74 between poor performance in MPUT and increased mortality at short and long term, thereby indicating  
75 that MPUT can be an alternative to WS in the slowness assessment with similar predictive capability  
76 for mortality <sup>23</sup>.

77 To our knowledge there is no study comparing the capability of WS and MPUT in predicting non-fatal  
78 adverse outcomes. Thus, this study aimed to investigate the capacity of slowness measurements (WS  
79 and MPUT) to predict non-fatal adverse consequences of frailty, primarily: decline in basic activities of  
80 daily living (BADLs); and secondarily: decline in instrumental activities of daily living (IADLs), fall,  
81 hospitalization, and incident disease.

## 82 **METHODS**

### 83 *Study population and design*

84 Participants were selected from the Lausanne cohort 65+ (Lc65+), an ongoing population-based  
85 longitudinal study investigating age-related frailty among persons aged 65 years and over living in  
86 Lausanne, Switzerland. Detailed description of the study design has been published previously <sup>25, 26</sup>.  
87 Briefly, participants were randomly selected from the official population register in three waves (2004,  
88 2009 and 2014). In 2004, the first sample included 1564 persons (born 1934 – 1938); in 2009, the  
89 second sample included 1489 persons (born 1939 – 1943); and in 2014, the third sample included 1678  
90 persons (born 1944 – 1948). Since then, participant follow-up assessments included annual postal

91 questionnaires as well as performance tests conducted every third year at the study evaluation site.  
92 The current prospective longitudinal analysis used data from the first and second samples at the age  
93 of 72-77 years in 2011 and 2016, respectively, as well as 1-year follow-up (2012 and 2017 for the first  
94 and second samples, respectively) and 4-year follow-up (2015 and 2020, respectively). Eligible  
95 participants were those who completed both the WS test and the MPUT in 2011 (first sample) or in  
96 2016 (second sample); the two samples were combined (**supplementary figure 1**). The protocol was  
97 approved by the Ethics Committee.

#### 98 *Walking speed (WS) and MPUT assessments*

99 WS was assessed by the time in seconds to walk a 20-meter distance at usual pace in a quiet, well-lit  
100 corridor. The MPUT was assessed by the time in seconds to pick up 12 small objects scattered on a  
101 table in front of seated participants with the dominant hand and to place them into a box as fast as  
102 possible <sup>24</sup>. WS and MPUT were dichotomized, according to the sex-specific 80<sup>th</sup> percentile (p80)  
103 distribution in the study samples, into normal/fast ( $\leq p80$ ) versus slow ( $> p80$ ) <sup>9</sup>.

#### 104 *Adverse frailty outcomes*

105 Our primary outcome of the adverse frailty consequences was decline in BADLs and our secondary  
106 outcomes included decline in IADLs, fall, hospitalization, and incident disease.

107 For our primary outcome, we used the change in difficulties in BADLs between baseline and each follow  
108 up. Difficulties in BADLs were defined as current difficulties or help received in at least one of Katz'  
109 activities (feeding, bathing, dressing, using the toilet, and getting up from bed or lying on a bed) <sup>27</sup>. The  
110 change between baseline and each follow up was further categorized into two groups, i.e., 'no change  
111 or improved' and 'declined'.

112 Difficulties in IADLs were defined as current difficulties or help received in at least one of Lawton's  
113 activities (housework, shopping, preparing meals, using a phone, preparing drugs and managing

114 money)<sup>28</sup>. Similarly for IADLs, the change between baseline and each follow up was used and further  
115 categorized into two groups, i.e., 'no change or decreased' and 'increased'.

116 For fall, participants were asked each year if they experienced a fall during the last 12 months ('zero',  
117 'one', 'two or more'). For 1-year follow up, the assessments of year 2012 and 2017 were considered  
118 for first and second samples, respectively. For 4-year follow up, all yearly assessments (2012, 2013,  
119 2014 and 2015 for the first sample; 2017, 2018, 2019 and 2020 for the second sample) were taken into  
120 account. The 4-year cumulative fall was constructed with the following categories: 'zero' (if the answer  
121 to the question was 'zero' each year); 'one' (if the answer 'one' was given only once); and 'two or more'  
122 (if the answer 'one' was repeated at least twice or the answer 'two or more' was given at least once  
123 over the yearly assessments).

124 For hospitalisation, participants were yearly asked how many times they were hospitalized during the  
125 last 12 months. The number of hospitalisations was categorized into three groups ('zero', 'one', 'two  
126 or more'). The 1-year and 4-year follow-ups were computed using a procedure similar to the one  
127 described for fall.

128 For medical diagnoses, participants were asked whether they suffered from or received treatment for  
129 any of the 14 following selected health conditions or diseases, diagnosed by a physician, over the last  
130 12 months: hypertension, myocardial ischemia, other heart disease, stroke, diabetes, chronic lung  
131 disease, asthma, osteoporosis, arthrosis or arthritis, malignant neoplasm, ulcer, Parkinson's,  
132 depression, and Alzheimer's. Using these data at baseline and short and long-term follow-ups, we  
133 defined incident disease as any new disease that was not mentioned at baseline but was reported at  
134 1-year or 4-year follow-up, respectively. The total number of incident diseases was categorized into  
135 three groups ('zero', 'one', 'two or more').

136 *Sociodemographic data*

137 Socio-demographic data included sex; age at baseline, i.e. age of first and second samples in 2011 and  
138 2016, respectively; educational level categorized, based on the International Standard Classification of  
139 Education (ISCED) <sup>29</sup>, as low (obligatory school or ISCED 0-2), medium (apprenticeship or ISCED 3) or  
140 high (college, university degree or equivalent or ISCED 4-8).

141 *Statistical analysis*

142 Descriptive statistics were used to summarize the characteristics of included participants. Results were  
143 expressed as the number and percentage of participants.

144 For each adverse outcome, separately for 1-year and 4-year follow up, we used two models: model 1  
145 included MPUT, sex and age at baseline; and model 2 included the same with WS as the predictor.  
146 Logistic regression (for decline in BADLs and IADLs) and multinomial (polytomous) logistic regression  
147 analyses (for fall, hospitalization and incident disease) were conducted, with adjustment for age, sex  
148 and respective values of each adverse outcome at baseline, and with separate models for 1-year and  
149 4-year follow up. For those adverse outcomes defined relative to baseline assessments (i.e. decline in  
150 BADLs or IADLs and incident disease), those with maximum values at baseline were excluded. The  
151 results were presented per relative risk (RR) and relative risk ratio (RRR) after logistic and multinomial  
152 logistic regression, respectively. In order to visualize the difference between models 1 and 2 in  
153 predicting each adverse outcome, separately for 1-year and 4-year follow up, we computed the area  
154 under the ROC curve (AUC) of both models after logistic regression. They were then compared by chi-  
155 squared tests using a non-parametric approach taking into account the correlated nature of the data  
156 <sup>30</sup>. In the logistic regressions, we considered the three-level variables (fall, hospitalization and incident  
157 disease) as two sets of level variables (zero versus one and zero versus two or more). For secondary  
158 outcomes, we used Bonferroni correction to account for multiple comparisons, and a two-tailed P-  
159 value <0.0125 (=0.05/4) was considered statistically significant. A sensitivity analysis was conducted  
160 after excluding the MPUT and WS outliers, using an outlier detection approach for skewed data <sup>31</sup>.

161 Statistical analyses were performed using Stata software version 16.0 (Stata Corp, College Station, TX,  
162 USA).

### 163 **RESULTS:**

164 The characteristics of included participants (who performed both MPUT and WS test, n=1887), values  
165 of both slowness assessments, and the prevalence of the adverse consequences of frailty at baseline  
166 are presented in **Table 1**. The majority of the participants were women (59.8%); the mean age was  
167 74.9±1.4 years. For all studied adverse consequences of frailty, the majority of the participants had no  
168 problem at baseline, except for medical diagnoses for which 73% had at least one diagnosis.  
169 **Supplementary table 1** presents the characteristics of the subgroups of participants who were slow  
170 (>p80) in WS or in MPUT. The characteristics of 79 individuals without WS data – hence not included  
171 in following analyses – but with MPUT data are presented in **Supplementary table 2**. This subgroup  
172 was slower and had worst outcomes in terms of functional difficulties, falls, hospitalisations, and  
173 medical diagnoses (**Supplementary table 3**).

174 The frequencies of primary (decline in BADLs) and secondary adverse outcomes (decline in IADLs, fall,  
175 hospitalization and incident disease) are summarized in **Table 2**. The prevalence of all the studied  
176 adverse outcomes increased over time; among them, the percentage of those experiencing at least  
177 one fall or hospitalization more than doubled.

178 Multivariable associations between both slowness assessments (WS and MPUT) and frailty adverse  
179 outcomes at 1-year and 4-year follow-up, adjusted for sex, age and respective values of frailty adverse  
180 outcomes at baseline, are presented in **Table 3**. Positive associations were observed at 1-year follow-  
181 up between slowness, either assessed by WS (RR=2.48; P-value <0.001) or by MPUT (RR=1.91; P-value  
182 <0.001), and decline in BADLs. These associations remained significant at 4-year follow-up for both WS  
183 (RR=2.28; P-value <0.001) and MPUT (RR=1.95; P-value <0.001). Overall, decline in BADLs was about  
184 twice as likely in slow individuals.



185 For decline in IADLs, the same pattern was observed, but its association with MPUT at 1-year follow-  
186 up did not reach significance after the Bonferroni correction (P-value <0.0125). Regarding other  
187 secondary outcomes, recurrent hospitalization was positively associated with slow WS or MPUT at  
188 short and long term follow ups. While WS was associated with multiple falls at 4-year follow-up  
189 (RRR=2.35; P-value <0.001), MPUT was associated with the incidence of one or more diseases at 1-  
190 year follow-up (RRR=1.52; P-value = 0.002) and with the incidence of two or more diseases at 4-year  
191 follow-up (RRR=1.74; P-value = 0.006).

192 **Figures 1 and 2** present the comparison between predictive capabilities of slow WS and MPUT for each  
193 frailty adverse outcome, separately for 1-year and 4-year follow-up, illustrated by AUC values of the  
194 two logistic regression models. There was no significant difference between predictive values of slow  
195 WS and MPUT for decline in BADLs (our primary outcome), at 1-year and 4-year follow-up, nor for the  
196 secondary outcomes (fall, hospitalization and incident disease) after the Bonferroni correction (P-value  
197 <0.0125), except for predicting decline in IADLs at 1-year follow-up (P-value =0.001) (**Supplementary**  
198 **table 4**).

199 Sensitivity analyses (after excluding the outliers of WS and/or MPUT) showed comparable results of  
200 multivariable analyses and the AUC of models (using WS and MPUT) after logistic regression.

## 201 **DISCUSSION**

202 In this study, those participants having both WS and MPUT measurements were included to compare  
203 the association between each slowness measurements with non-fatal adverse consequences of frailty  
204 at short and long term. Furthermore, the capacity of both measurements in predicting the short and  
205 long term adverse frailty outcomes was compared.

206 The significant associations between MPUT and decline in BADLs and similar capability of MPUT  
207 compared to WS for predicting decline in BADLs support the MPUT as an alternative slowness  
208 measurement. It is worth mentioning that slowness, as a potential geriatric syndrome, is a complex  
209 construct acting on the continuum between normal aging and pathologic aging. The symptomatology

210 of slowing is diverse; for instance, in healthy community-dwelling individuals, increasing age is  
211 associated with slow walking, reductions in processing speed (slow thinking), and increased apathy  
212 (mood). This viewpoint suggests that the presence of slowing in one aspect could prompt to be aware  
213 of the presence of other slowing aspects<sup>32, 33</sup>. A study of slowing aspects in community-dwelling older  
214 people showed that slowing in walking is associated with slowing in thinking<sup>34</sup>. MPUT as a  
215 psychomotor speed test may be considered to assess slowness of one domain across multiple  
216 functional domains<sup>35</sup>.

217 Several trials examined the associations between different physical frailty indicators including WS and  
218 ADL<sup>13, 15, 36</sup> or compared predictive validity of WS with other commonly used performance-based  
219 measures (such as Short Physical Performance Battery (SPPB), Timed Up and Go test (TUG), grip  
220 strength, and physical activity) for the onset of ADL difficulty in older adults<sup>37, 38</sup>. These studies  
221 indicated that older people with slower WS have a higher risk of developing ADL disability. Meanwhile,  
222 previous studies emphasized the possible influence of the follow-up duration when comparing the  
223 predictive capabilities of different measures regarding the development of ADL disability. For instance,  
224 while WS predicts the development of ADL disability after a follow-up of one year, physical activity  
225 predicts it better after a longer follow-up<sup>38-40</sup>. It may explain the different predictive capabilities of WS  
226 and MPUT for decline in IADLs, at 1-year follow-up in our study that was the only difference between  
227 predictive capabilities of WS and MPUT for all outcomes. This may also emphasize the importance of  
228 recurrent measurement of frailty<sup>41</sup>. Regarding MPUT, although manual dexterity has been considered  
229 crucial for ADL in some studies<sup>42, 43</sup>, to our knowledge there is no study assessing the association  
230 between MPUT – as an indicator of slowness – and functional decline, and further comparing its  
231 predictive capability for functional decline with other measures.

232 Regarding fall, it should be noted that the relationship between WS and fall may be nonlinear, i.e. not  
233 only slower, but also faster individuals are at a higher risk of falling. This relationship was explained by  
234 the fact that the slower older people are less active, generally sicker and more likely to fall inside home,

235 while those who are fast are more likely to fall outside home because they are more exposed to  
236 environmental and behavioral risks<sup>36, 44, 45</sup>. It highlights the need to investigate the site of falls and the  
237 relationship between extremes (slowest and fastest) in MPUT and fall.

238 For recurrent hospitalization, our results suggest that MPUT may be an alternative slowness  
239 measurement. Meanwhile, previous studies showed heterogeneous results about WS as an  
240 independent marker of hospitalization<sup>12, 46, 47</sup>. It should be noted that hospitalization might occur for  
241 a variety of reasons, including elective admissions, the recurrent nature of some diseases<sup>48</sup> or hospital-  
242 acquired complications<sup>49</sup>.

243 Regarding incident disease, a study among older patients undergoing cardiac surgery also concluded  
244 that slow WS could not be identified as independent predictor for major morbidity<sup>50</sup>. The majority of  
245 studies investigating the association between WS and incident disease focused on onset of specific  
246 diseases such as cardiovascular diseases (CVD), cancer, dementia or depression<sup>51-53</sup>. The results are  
247 also disease specific according to a meta-analysis, which reported a link between slow WS and the  
248 incidence of CVD in older adults, while no significant association was found between WS and the  
249 incidence of cancer<sup>51</sup>.

250 Of the five frailty criteria, slowness is the one most strongly associated with poor quality of life<sup>54</sup>. It is  
251 an important measure in comprehensive geriatric assessment, with predictive value for adverse  
252 outcomes such as hospitalization, institutionalization, mortality and falls<sup>55</sup>. Slowness is considered as  
253 a red flag for functional decline in older adults, contributing to the development of the frailty  
254 phenotype<sup>11</sup>. Our study confirms previous associations reported between slow walking speed and the  
255 incidence of disability in community-dwelling older adults<sup>56, 57</sup>, and extends these associations to an  
256 alternative measure of slowness. In research settings, MPUT may be useful if space or other  
257 environmental characteristics hamper the completion of WS in valid conditions. A systematic review  
258 reported large variations in methodologies and descriptions of walking tests in the literature<sup>58</sup>. In  
259 clinical settings, the measurement of WS in older people may be challenging. A study among

260 hospitalized older adults reported that a minority were able to complete WS, while 95% could  
261 successfully have a handgrip strength measurement<sup>59</sup>. Individuals unable to complete WS are usually  
262 imputed as meeting the slowness criterion, which results in an overestimation of frailty. Of the  
263 participant in the present study who were unable to complete WS but able to complete MPUT, less  
264 than half met the MPUT criterion for slowness.

265 The main strength of our study included a large sample of older community-dwelling adults who  
266 performed both MPUT and WS tests during the same assessment, and a short and long follow-up  
267 period that allowed us to compare predictive capabilities of both assessments for the non-fatal frailty  
268 adverse outcomes. This study also has several limitations. First, we used the sex-specific p80  
269 distribution in the study samples for discrimination between slow vs. normal/fast for both WS and  
270 MPUT measurements. The optimality of the cut-off, especially because population-based normal  
271 values for MPUT are not available, needs to be further studied. Second, MPUT was initially developed  
272 to evaluate hand motor activity and sensory impairment; thus it uses small objects that may be difficult  
273 to grab. For increasing the specificity in slowness measurement, its modification with larger, easy-to-  
274 grab objects may be needed.

#### 275 **CONCLUSION AND IMPLICATIONS**

276 MPUT may be an alternative measurement of slowness and can predict functional decline. No  
277 significant difference in predictive capabilities of MPUT and WS for specific non-fatal adverse  
278 consequences of frailty including fall, hospitalizations and incident disease are promising in favor of  
279 using MPUT as a measurement of slowness.

280 **References:**

- 281 1. Brivio P, Paladini MS, Racagni G, et al. From Healthy Aging to Frailty: In Search of the Underlying  
282 Mechanisms. *Curr Med Chem*. 2019;26(20):3685-3701.
- 283 2. He W, Goodkind D, Kowal PR. An aging world: 2015. United States Census Bureau Washington,  
284 DC 2016.
- 285 3. Kohli R, statistique SOfdl. Les scénarios de l'évolution de la population de la Suisse: 2015-2045:  
286 Office fédéral de la statistique 2015.
- 287 4. Mousa A, Savva GM, Mitnitski A, et al. Is frailty a stable predictor of mortality across time?  
288 Evidence from the Cognitive Function and Ageing Studies. *Age and ageing*. 2018;47(5):721-727.
- 289 5. Dent E, Martin FC, Bergman H, et al. Management of frailty: opportunities, challenges, and  
290 future directions. *Lancet*. 2019;394(10206):1376-1386.
- 291 6. Vermeiren S, Vella-Azzopardi R, Beckwee D, et al. Frailty and the prediction of negative health  
292 outcomes: a meta-analysis. *Journal of the American Medical Directors Association*.  
293 2016;17(12):1163. e1161-1163. e1117.
- 294 7. Yang X, Lupón J, Vidán MT, et al. Impact of frailty on mortality and hospitalization in chronic  
295 heart failure: a systematic review and meta-analysis. *Journal of the American Heart Association*.  
296 2018;7(23):e008251.
- 297 8. Buta BJ, Walston JD, Godino JG, et al. Frailty assessment instruments: Systematic  
298 characterization of the uses and contexts of highly-cited instruments. *Ageing Res Rev*.  
299 2016;26:53-61.
- 300 9. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *The*  
301 *journals of gerontology Series A, Biological sciences and medical sciences*. 2001;56(3):M146-156.
- 302 10. Bouillon K, Kivimaki M, Hamer M, et al. Measures of frailty in population-based studies: an  
303 overview. *BMC geriatrics*. 2013;13:64.
- 304 11. de Oliveira DC, de Oliveira Máximo R, Ramírez PC, et al. Is slowness a better discriminator of  
305 disability than frailty in older adults? *Journal of cachexia, sarcopenia and muscle*.  
306 2021;12(6):2069-2078.
- 307 12. Cesari M, Kritchevsky SB, Penninx BW, et al. Prognostic value of usual gait speed in well-  
308 functioning older people—results from the Health, Aging and Body Composition Study. *Journal*  
309 *of the American Geriatrics Society*. 2005;53(10):1675-1680.
- 310 13. Castell M-V, Sánchez M, Julián R, et al. Frailty prevalence and slow walking speed in persons age  
311 65 and older: implications for primary care. *BMC family practice*. 2013;14(1):1-9.
- 312 14. Fritz S, Lusardi M. White paper: "walking speed: the sixth vital sign". *J Geriatr Phys Ther*.  
313 2009;32(2):46-49.
- 314 15. Perera S, Patel KV, Rosano C, et al. Gait speed predicts incident disability: a pooled analysis.  
315 *Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences*. 2016;71(1):63-71.
- 316 16. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. *Jama*.  
317 2011;305(1):50-58.
- 318 17. Pradeep Kumar D, Toosizadeh N, Mohler J, et al. Sensor-based characterization of daily walking:  
319 a new paradigm in pre-frailty/frailty assessment. *BMC geriatrics*. 2020;20(1):164.
- 320 18. Takayanagi N, Sudo M, Yamashiro Y, et al. Relationship between Daily and In-laboratory Gait  
321 Speed among Healthy Community-dwelling Older Adults. *Sci Rep*. 2019;9(1):3496.
- 322 19. Van Ancum JM, van Schooten KS, Jonkman NH, et al. Gait speed assessed by a 4-m walk test is  
323 not representative of daily-life gait speed in community-dwelling adults. *Maturitas*.  
324 2019;121:28-34.
- 325 20. Kawai H, Obuchi S, Watanabe Y, et al. Association between Daily Living Walking Speed and  
326 Walking Speed in Laboratory Settings in Healthy Older Adults. *Int J Environ Res Public Health*.  
327 2020;17(8).
- 328 21. Moberg E. Objective methods for determining the functional value of sensibility in the hand. *J*  
329 *Bone Joint Surg Br*. 1958;40-b(3):454-476.

- 330 22. Ng CL, Ho DD, Chow SP. The Moberg pickup test: results of testing with a standard protocol. *J*  
331 *Hand Ther.* 1999;12(4):309-312.
- 332 23. Meyer ML, Fustinoni S, Henchoz Y, et al. Slowness Predicts Mortality: A Comparative Analysis of  
333 Walking Speed and Moberg Picking-Up Tests. *Journal of the American Medical Directors*  
334 *Association.* 2021;22(8):1652-1657.e1652.
- 335 24. Santos-Eggimann B, Ballan K, Fustinoni S, et al. Measuring Slowness in Old Age: Times to  
336 Perform Moberg Picking-Up and Walking Speed Tests. *Journal of the American Medical Directors*  
337 *Association.* 2020;21(11):1729-1734.e1722.
- 338 25. Santos-Eggimann B, Karmaniola A, Seematter-Bagnoud L, et al. The Lausanne cohort Lc65+: a  
339 population-based prospective study of the manifestations, determinants and outcomes of  
340 frailty. *BMC geriatrics.* 2008;8:20.
- 341 26. Henchoz Y, Blanco JM, Fustinoni S, et al. Cohort Profile: The Lausanne cohort 65+ (Lc65+). *Int J*  
342 *Epidemiol.* 2021.
- 343 27. Katz S, Ford AB, Heiple KG, et al. Studies of illness in the aged: recovery after fracture of the hip.  
344 *Journal of gerontology.* 1964;19(3):285-293.
- 345 28. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities  
346 of daily living. *The gerontologist.* 1969;9(3\_Part\_1):179-186.
- 347 29. Division of Statistics on Education; Office of Statistics. International Standard Classification of  
348 Education (ISCED): Abridged edition. Paris : Unesco, 1975. 1975.
- 349 30. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated  
350 receiver operating characteristic curves: a nonparametric approach. *Biometrics.* 1988:837-845.
- 351 31. Hubert M, Van der Veeken S. Outlier detection for skewed data. *Journal of Chemometrics: A*  
352 *Journal of the Chemometrics Society.* 2008;22(3-4):235-246.
- 353 32. Sloane PD, Warshaw G. Should Slowing Be Considered a Distinct Geriatric Syndrome? *Journal of*  
354 *the American Medical Directors Association.* 2022;23(1):20-22.
- 355 33. van de Schraaf SAJ, Rhodius-Meester HFM, Aben L, et al. Slowing: A Vascular Geriatric  
356 Syndrome? *Journal of the American Medical Directors Association.* 2022;23(1):47-53.e42.
- 357 34. Martin KL, Blizzard L, Wood AG, et al. Cognitive function, gait, and gait variability in older  
358 people: a population-based study. *The journals of gerontology Series A, Biological sciences and*  
359 *medical sciences.* 2013;68(6):726-732.
- 360 35. Albert SM, Bear-Lehman J, Burkhardt A. Mild depressive symptoms, self-reported disability, and  
361 slowing across multiple functional domains. *Int Psychogeriatr.* 2012;24(2):253-260.
- 362 36. Guedes RC, Dias R, Neri AL, et al. Frailty syndrome in Brazilian older people: a population based  
363 study. *Cien Saude Colet.* 2020;25(5):1947-1954.
- 364 37. Wennie Huang WN, Perera S, VanSwearingen J, et al. Performance measures predict onset of  
365 activity of daily living difficulty in community-dwelling older adults. *J Am Geriatr Soc.*  
366 2010;58(5):844-852.
- 367 38. Vermeulen J, Neyens JC, van Rossum E, et al. Predicting ADL disability in community-dwelling  
368 elderly people using physical frailty indicators: a systematic review. *BMC geriatrics.* 2011;11:33.
- 369 39. Balzi D, Lauretani F, Barchielli A, et al. Risk factors for disability in older persons over 3-year  
370 follow-up. *Age and Ageing.* 2010;39(1):92-98.
- 371 40. Gill TM, Williams CS, Tinetti ME. Assessing risk for the onset of functional dependence among  
372 older adults: the role of physical performance. *Journal of the American Geriatrics Society.*  
373 1995;43(6):603-609.
- 374 41. Thompson MQ, Theou O, Tucker GR, et al. Recurrent Measurement of Frailty Is Important for  
375 Mortality Prediction: Findings from the North West Adelaide Health Study. *J Am Geriatr Soc.*  
376 2019;67(11):2311-2317.
- 377 42. Rabah A, Le Boterff Q, Carment L, et al. A novel tablet-based application for assessment of  
378 manual dexterity and its components: a reliability and validity study in healthy subjects. *J*  
379 *Neuroeng Rehabil.* 2022;19(1):35.
- 380 43. Lemon RN. Descending pathways in motor control. *Annu Rev Neurosci.* 2008;31:195-218.

- 381 44. Kelsey JL, Berry SD, Procter-Gray E, et al. Indoor and outdoor falls in older adults are different:  
382 the maintenance of balance, independent living, intellect, and Zest in the Elderly of Boston  
383 Study. *J Am Geriatr Soc.* 2010;58(11):2135-2141.
- 384 45. Buchner DM, Larson EB, Wagner EH, et al. Evidence for a non-linear relationship between leg  
385 strength and gait speed. *Age Ageing.* 1996;25(5):386-391.
- 386 46. Cawthon PM, Fox KM, Gandra SR, et al. Do muscle mass, muscle density, strength, and physical  
387 function similarly influence risk of hospitalization in older adults? *J Am Geriatr Soc.*  
388 2009;57(8):1411-1419.
- 389 47. Woo J, Ho SC, Yu AL. Walking speed and stride length predicts 36 months dependency,  
390 mortality, and institutionalization in Chinese aged 70 and older. *J Am Geriatr Soc.*  
391 1999;47(10):1257-1260.
- 392 48. Frick U, Frick H, Langguth B, et al. The revolving door phenomenon revisited: time to  
393 readmission in 17'145 [corrected] patients with 37'697 hospitalisations at a German psychiatric  
394 hospital. *PLoS One.* 2013;8(10):e75612.
- 395 49. Bail K, Goss J, Draper B, et al. The cost of hospital-acquired complications for older people with  
396 and without dementia; a retrospective cohort study. *BMC Health Serv Res.* 2015;15:91.
- 397 50. Prudon I, Noyez L, H VANS, et al. Is gait speed improving performance of the EuroSCORE II for  
398 prediction of early mortality and major morbidity in the elderly? *J Cardiovasc Surg (Torino).*  
399 2016;57(4):592-597.
- 400 51. Veronese N, Stubbs B, Volpato S, et al. Association between gait speed with mortality,  
401 cardiovascular disease and cancer: a systematic review and meta-analysis of prospective cohort  
402 studies. *Journal of the American Medical Directors Association.* 2018;19(11):981-988. e987.
- 403 52. Waite LM, Grayson DA, Piguat O, et al. Gait slowing as a predictor of incident dementia: 6-year  
404 longitudinal data from the Sydney Older Persons Study. *J Neurol Sci.* 2005;229-230:89-93.
- 405 53. Veronese N, Stubbs B, Trevisan C, et al. Poor Physical Performance Predicts Future Onset of  
406 Depression in Elderly People: Progetto Veneto Anziani Longitudinal Study. *Phys Ther.*  
407 2017;97(6):659-668.
- 408 54. Henchoz Y, Büla C, Guessous I, et al. Association between physical frailty and quality of life in a  
409 representative sample of community-dwelling Swiss older people. *The journal of nutrition,*  
410 *health & aging.* 2017;21(5):585-592.
- 411 55. Peel NM, Kuys SS, Klein K. Gait speed as a measure in geriatric assessment in clinical settings: a  
412 systematic review. *The Journals of Gerontology: Series A.* 2013;68(1):39-46.
- 413 56. Shimada H, Makizako H, Doi T, et al. Incidence of disability in frail older persons with or without  
414 slow walking speed. *Journal of the American Medical Directors Association.* 2015;16(8):690-696.
- 415 57. Provencher V, Béland F, Demers L, et al. Are frailty components associated with disability in  
416 specific activities of daily living in community-dwelling older adults? A multicenter Canadian  
417 study. *Archives of gerontology and geriatrics.* 2017;73:187-194.
- 418 58. Graham JE, Ostir GV, Fisher SR, et al. Assessing walking speed in clinical research: a systematic  
419 review. *Journal of evaluation in clinical practice.* 2008;14(4):552-562.
- 420 59. Ibrahim K, Howson FFA, Culliford DJ, et al. The feasibility of assessing frailty and sarcopenia in  
421 hospitalised older people: a comparison of commonly used tools. *BMC geriatrics.* 2019;19(1):42.

422

**Table 1: Characteristics of participants (N = 1887)**

Gender, n (%)	
Men	759 (40.2)
Women	1128 (59.8)
Age, years, mean $\pm$ SD	74.9 $\pm$ 1.4
Education, n (%)	
High	773 (41.1)
Middle	748 (39.7)
Low	361 (19.2)
Height (cm), mean $\pm$ SD	164.7 $\pm$ 8.8
Weight (kg), mean $\pm$ SD	73.7 $\pm$ 14.9
BMI, mean $\pm$ SD	27.1 $\pm$ 4.8
MPUT, S, mean $\pm$ SD	13.1 $\pm$ 2.8
Slowness (MPUT), n (%)	
Yes	376 (19.9)
No	1511 (80.1)
Walking speed, S, mean $\pm$ SD	16.9 $\pm$ 3.9
Slowness (WS), n (%)	
Yes	376 (19.9)
No	1511 (80.1)
Difficulties in BADLs, n (%)	
Yes	267 (14.2)
No	1620 (85.8)
Difficulties in IADLs, n (%)	
Yes	801 (42.5)
No	1086 (57.5)
Fall, n (%)	
No	1485 (78.8)
One	317 (16.8)
Two or more	82 (4.4)
Hospitalisations, n (%)	
No	1583 (83.9)
One time	239 (12.7)
Two times or more	65 (3.4)
Medical Diagnoses, n (%)	
No	509 (27.0)
One	670 (35.5)
Two or more	708 (37.5)

Abbreviations: MPUT, Moberg picking-up test (time in seconds); WS, walking speed (time in seconds); BADLs, Basic activities of daily living; IADLs, Instrumental activities of daily living.



**Table 2: Adverse consequences of frailty at 1-year and 4-year follow-up**

	1-year follow-up	4-year follow-up
<b>Primary outcome</b>		
Decline in BADLs		
No change/improved	1663 (92.0)	1470 (86.1)
Declined	144 (8.0)	237 (13.9)
<b>Secondary outcomes</b>		
Decline in IADLs		
No change/improved	1384 (78.5)	1138 (67.5)
Declined	379 (21.5)	549 (32.5)
Fall		
No	1408 (78.0)	815 (48.1)
One	316 (17.5)	394 (23.3)
Two or more	82 (4.5)	484 (28.6)
Hospitalisations		
No	1397 (80.6)	747 (48.5)
One time	236 (13.6)	326 (21.2)
Two times or more	101 (5.8)	466 (30.3)
Incident diseases		
No	1305 (72.9)	1059 (63.4)
One	414 (23.1)	450 (27.0)
Two or more	72 (4.0)	160 (9.6)

Abbreviations: BADLs, Basic activities of daily living; IADLs, Instrumental activities of daily living.  
Values are expressed as n (%).

**Table 3:** Multivariable association between slowness (assessed by either WS or MPUT) and frailty adverse outcomes at 1-year and 4-year follow-up

	Slowness based on WS				Slowness based on MPUT			
	1-year	p-value	4-year	p-value	1-year	p-value	4-year	p-value
<b>Primary outcome</b>								
Decline in BADLs <sup>1</sup>								
No change/improved	1 (ref.)		1 (ref.)		1 (ref.)		1 (ref.)	
Declined	<b>2.48 (1.78 – 3.48)</b>	<b>&lt;0.001</b>	<b>2.28 (1.77 – 2.94)</b>	<b>&lt;0.001</b>	<b>1.91 (1.37 – 2.66)</b>	<b>&lt;0.001</b>	<b>1.95 (1.66 – 3.08)</b>	<b>&lt;0.001</b>
<b>Secondary outcomes</b>								
Decline in IADLs <sup>1</sup>								
No change/ improved	1 (ref.)		1 (ref.)		1 (ref.)		1 (ref.)	
Declined	<b>1.92 (1.58 – 2.33)</b>	<b>&lt;0.001</b>	<b>1.79 (1.55 – 2.06)</b>	<b>&lt;0.001</b>	1.26 (1.02 - 1.55)	0.035	<b>1.35 (1.15 - 1.57)</b>	<b>&lt;0.001</b>
Fall <sup>3</sup>								
No fall	1 (ref.)		1 (ref.)		1 (ref.)		1 (ref.)	
One time	1.26 (0.92 - 1.71)	0.145	1.12 (0.79 - 1.58)	0.524	1.10 (0.81 - 1.50)	0.553	0.89 (0.64 - 1.23)	0.482
Two or more times	1.78 (1.05 - 3.01)	0.032	<b>2.35 (1.74 - 3.17)</b>	<b>&lt;0.001</b>	1.32 (0.76 - 2.27)	0.323	1.36 (1.01 – 1.83)	0.043
Hospitalisations <sup>2</sup>								
No	1 (ref.)		1 (ref.)		1 (ref.)		1 (ref.)	
One time	<b>1.83 (1.32 - 2.53)</b>	<b>&lt;0.001</b>	1.14 (0.78 – 1.66)	0.502	1.32 (0.94 - 1.85)	0.108	0.90 (0.62 - 1.29)	0.559
Two times or more	<b>2.60 (1.66– 4.07)</b>	<b>&lt;0.001</b>	<b>2.75 (2.04 - 3.71)</b>	<b>&lt;0.001</b>	<b>1.88 (1.18 – 2.99)</b>	<b>0.007</b>	<b>1.51 (1.13 - 2.04)</b>	<b>0.006</b>
Incident diseases <sup>2</sup>								
No	1 (ref.)		1 (ref.)		1 (ref.)		1 (ref.)	
One more disease	1.33 (1.00 – 1.76)	0.048	0.89 (0.65 – 1.20)	0.441	<b>1.52 (1.16 – 2.00)</b>	<b>0.002</b>	1.27 (0.96 – 1.69)	0.099
Two or more diseases	1.37 (0.77 - 2.42)	0.283	1.43 (0.95 - 2.16)	0.088	1.12 (0.62 - 2.03)	0.712	<b>1.74 (1.17 - 2.59)</b>	<b>0.006</b>

Abbreviations: BADLs, Basic activities of daily living; IADLs, Instrumental activities of daily living; WS, walking speed (time in seconds); MPUT, Moberg Picking-Up Test (time in seconds).

All analyses were adjusted for sex, age and respective values of frailty adverse outcomes at baseline (i.e. BADLs at baseline for decline in BADLs, IADLs at baseline for decline in IADLs and so on).

<sup>1</sup> Results are expressed as relative risk (RR) (95% confidence interval) using Logistic regression

<sup>2</sup> Results are expressed as relative risk ratio (RRR) (95% confidence interval) using Multinomial (polytomous) logistic regression.




Figure 1: ROC of model 1: Moberg Picking-Up test (MPUT) in red and model 2: Walking speed (WS) in blue in predicting frailty adverse outcomes at 1-year follow up  
 Abbreviations: BADLs, Basic activities of daily living; IADLs; Instrumental activities of daily living  
 \*Significant difference for “Decline in IADLs”





Figure 2: ROC of model 1: Moberg Picking-Up test (MPUT) in red and model 2: Walking speed (WS) in blue in predicting frailty adverse outcomes at 4-year follow up  
 Abbreviations: BADLs, Basic activities of daily living; IADLs; Instrumental activities of daily living

**Supplementary figure 1: Procedure of participants' selection**



Abbreviations: WS, walking speed (time in seconds); MPUT, Moberg Picking-Up Test (time in seconds).

**Supplementary table 1: Characteristics of participants with slow WS or MPUT**

	Slow in WS (N = 376)	Slow in MPUT (N = 376)
Gender, n (%)		
Men	151 (40.2)	151 (40.2)
Women	225 (59.8)	225 (59.8)
Age, years, mean $\pm$ SD	75.2 $\pm$ 1.4	75.0 $\pm$ 1.4
Education, n (%)		
High	119 (31.9)	140 (37.5)
Middle	150 (40.2)	148 (39.7)
Low	104 (27.9)	85 (22.8)
Height (cm), mean $\pm$ SD	162.5 $\pm$ 9.4	163.5 $\pm$ 9.6
Weight (kg), mean $\pm$ SD	77.8 $\pm$ 17.3	75.9 $\pm$ 16.5
BMI, mean $\pm$ SD	29.4 $\pm$ 5.7	28.3 $\pm$ 5.4
MPUT, S, mean $\pm$ SD	14.7 $\pm$ 3.5	17.3 $\pm$ 3.0
Slowness (MPUT), n (%)		
Yes	153 (40.7)	376 (100.0)
No	223 (59.3)	0 (0.0)
Walking speed, S, mean $\pm$ SD	22.4 $\pm$ 5.4	19.2 $\pm$ 5.9
Slowness (WS), n (%)		
Yes	376 (100.0)	153 (40.7)
No	0 (0.0)	223 (59.3)
Difficulties in BADLs, n (%)		
Yes	128 (34.0)	91 (24.2)
No	248 (66.0)	285 (75.8)
Difficulties in IADLs, n (%)		
Yes	265 (70.5)	218 (58.0)
No	111 (29.5)	158 (42.0)
Fall, n (%)		
No	266 (71.3)	276 (73.6)
One	73 (19.6)	66 (17.6)
Two or more	34 (9.1)	33 (8.8)
Hospitalisations, n (%)		
No	285 (75.8)	300 (79.8)
One time	67 (17.8)	59 (15.7)
Two times or more	24 (6.4)	17 (4.5)
Medical Diagnoses, n (%)		
No	55 (14.6)	73 (19.4)
One	110 (29.3)	119 (31.7)
Two or more	211 (56.1)	184 (48.9)

Abbreviations: MPUT, Moberg picking-up test (time in seconds); WS, walking speed (time in seconds); BADLs, Basic activities of daily living; IADLs, Instrumental activities of daily living.

**Supplementary table 2: Baseline characteristics of those participants having MPUT and not WS (N = 79)**

---

Gender, n (%)	
Men	17 (21.5)
Women	62 (78.5)
Age, years, mean $\pm$ SD	75.3 $\pm$ 1.5
Education, n (%)	
High	26 (33.3)
Middle	30 (38.5)
Low	22 (28.2)
Height (cm), mean $\pm$ SD	160.8 $\pm$ 7.7
Weight (kg), mean $\pm$ SD	73.2 $\pm$ 16.4
BMI, mean $\pm$ SD	28.5 $\pm$ 5.4
MPUT, S, mean $\pm$ SD	15.4 $\pm$ 4.8
Slowness (MPUT), n (%)	
Yes	36 (45.6)
No	43 (54.4)
Difficulties in BADLs, n (%)	
Yes	39 (49.4)
No	40 (50.6)
Difficulties in IADLs, n (%)	
Yes	70 (88.6)
No	9 (11.4)
Fall, n (%)	
No	51 (64.6)
One	16 (20.2)
Two or more	12 (15.2)
Hospitalisations, n (%)	
No	47 (59.5)
One time	18 (22.8)
Two times or more	14 (17.7)
Medical Diagnoses, n (%)	
No	5 (6.3)
One	10 (12.7)
Two or more	64 (81.0)

---

Abbreviations: MPUT, Moberg picking-up test (time in seconds); WS, walking speed (time in seconds); BADLs, Basic activities of daily living; IADLs, Instrumental activities of daily living.

**Supplementary table 3: Adverse consequences of frailty at 1-year and 4-year follow-up** (Those having MPUT and not WS, N = 79)

	<b>1-year follow-up</b>	<b>4-year follow-up</b>
<b>Primary outcome</b>		
Decline in BADLs		
No change/improved	52 (81.2)	30 (57.7)
Declined	12 (18.8)	22 (42.3)
<b>Secondary outcomes</b>		
Decline in IADLs		
No change/improved	46 (73.0)	29 (56.9)
Declined	17 (27.0)	22 (43.1)
Fall		
No	41 (64.1)	19 (33.9)
One	12 (18.7)	6 (10.7)
Two or more	11 (17.2)	31 (55.4)
Hospitalisations		
No	39 (65.0)	12 (24.5)
One time	16 (26.7)	5 (10.2)
Two times or more	5 (8.3)	32 (65.3)
Incident diseases		
No	38 (62.3)	30 (63.8)
One	17 (27.9)	10 (21.3)
Two or more	6 (9.8)	7 (14.9)

Abbreviations: BADLs, Basic activities of daily living; IADLs, Instrumental activities of daily living. Values are expressed as n (%).



**Supplementary table 4: Summary of the results for predicting frailty adverse outcomes**

	1-year Follow-up				4-year Follow-up			
	AUC	SE	95% CI	p-value	AUC	SE	95% CI	p-value
<b>Primary outcome</b>								
<b>Decline in BADLs*</b>				0.328				0.413
MPUT	0.63	0.025	0.58 – 0.67		0.62	0.020	0.58 – 0.66	
WS		0.024			0.63	0.021	0.59 – 0.67	
	0.65		0.60 – 0.69					
<b>Secondary outcomes</b>								
<b>Decline in IADLs*</b>				0.001				0.037
MPUT	0.56	0.017	0.53 – 0.59		0.58	0.015	0.55 – 0.61	
WS	0.61	0.017	0.58 – 0.64		0.61	0.015	0.59 – 0.64	
<b>Fall (0 vs 1)</b>				0.842				0.633
MPUT	0.61	0.017	0.58 – 0.65		0.60	0.017	0.57 – 0.63	
WS	0.62	0.017	0.58 – 0.65		0.60	0.017	0.57 – 0.64	
<b>Fall (0 vs ≥2)</b>				0.041				0.141
MPUT	0.78	0.029	0.72 – 0.84		0.69	0.015	0.66 – 0.72	
WS	0.80	0.028	0.74 – 0.85		0.71	0.015	0.68 – 0.74	
<b>Hospitalisation (0 vs 1)</b>				0.274				0.876
MPUT	0.60	0.021	0.56 – 0.64		0.58	0.019	0.54 – 0.62	
WS	0.62	0.020	0.58 – 0.66		0.58	0.019	0.54 – 0.62	
<b>Hospitalisation (0 vs ≥2)</b>				0.099				0.052
MPUT	0.69	0.031	0.63 – 0.75		0.61	0.017	0.58 – 0.64	
WS	0.72	0.028	0.67 – 0.78		0.64	0.017	0.61 – 0.67	
<b>Incident disease (0 vs 1)*</b>				0.303				0.915
MPUT	0.56	0.016	0.53 – 0.60		0.53	0.016	0.50 – 0.56	
WS	0.55	0.016	0.52 – 0.58		0.53	0.016	0.50 – 0.56	
<b>Incident disease (0 vs ≥2)*</b>				0.613				0.518
MPUT	0.58	0.034	0.51 – 0.65		0.57	0.025	0.52 – 0.62	
WS	0.59	0.034	0.52 – 0.65		0.56	0.024	0.51 – 0.61	

Abbreviations: BADLs, Basic activities of daily living; IADLs, Instrumental activities of daily living; AUC, area under the ROC curve; SE, Standard error; CI, Confidence interval.

Model 1 included Moberg picking-up test (MPUT) (time in seconds), sex, age and respective values of frailty adverse outcomes at baseline (i.e. BADLs at baseline for decline in BADLs, IADLs at baseline for decline in IADLs and so on); and model 2 included walking speed (WS) (time in seconds), sex, age and respective values of frailty adverse outcomes at baseline. Models were compared by chi-squared tests.

\*Those with maximum values of related frailty adverse outcomes at baseline were excluded from the analysis.